We are live on ! Find out more
HS

HighVista Strategies Portfolio holdings

AUM $362M
1-Year Est. Return 230.96%
This Fund
S&P 500
This Quarter Est. Return
+5.82%
1 Year Est. Return
+230.96%
3 Year Est. Return
+518.4%
5 Year Est. Return
+644.94%
10 Year Est. Return
+2,223.31%
AUM
$123M
AUM Growth
-$45.7M
Cap. Flow
-$44.3M
Cap. Flow %
-36.11%
Top 10 Hldgs %
29.13%
Holding
142
New
37
Increased
19
Reduced
19
Closed
34

Top Buys

Rank Stock Value
1
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$3.21M
2
ACI icon
Albertsons Companies
ACI
+$3.18M
3
OSH
Oak Street Health, Inc.
OSH
+$2.89M
4
IMVT icon
Immunovant
IMVT
+$2.84M
5
SGEN
Seagen Inc. Common Stock
SGEN
+$2.49M

Top Sells

Rank Stock Value
1
DELL icon
Dell
DELL
+$14.3M
2
MA icon
Mastercard
MA
+$12.9M
3
FISV
Fiserv Inc
FISV
+$8.83M
4
V icon
Visa
V
+$8.72M
5
MSDAU
MSD Acquisition Corp. Unit
MSDAU
+$5.05M

Sector Composition

Rank Sector Weight
1 Healthcare 67.14%
2 Technology 10.92%
3 Consumer Discretionary 4.92%
4 Financials 4.39%
5 Communication Services 4.16%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TERN
26
DELISTED
Terns Pharmaceuticals
TERN
$1.74M 1.42%
146,854
+69,510
+90% +$664K
ACLX
27
DELISTED
Arcellx
ACLX
$1.67M 1.36%
+54,280
New +$1.65M
RPTX
28
DELISTED
Repare Therapeutics
RPTX
$1.62M 1.32%
164,890
– –
ACRS icon
29
Aclaris Therapeutics
ACRS
$870M
$1.6M 1.3%
197,803
+10,184
+5% +$129K
DYN icon
30
Dyne Therapeutics
DYN
$4.95B
$1.18M 0.96%
102,431
– –
KDNY
31
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$1.15M 0.93%
49,495
– –
CRM icon
32
Salesforce
CRM
$161B
$1.12M 0.91%
5,610
+3,340
+147% +$564K
SRPT icon
33
Sarepta Therapeutics
SRPT
$1.89B
$1.06M 0.87%
7,713
– –
MSFT icon
34
Microsoft
MSFT
$3.73T
$1.05M 0.85%
3,640
+120
+3% +$30.6K
ACAD icon
35
Acadia Pharmaceuticals
ACAD
$5.09B
$1.05M 0.85%
55,574
-1,044
-2% -$19.9K
DBC icon
36
Invesco DB Commodity Index Tracking Fund
DBC
$1.72B
$1.01M 0.82%
42,396
– –
VRNA
37
DELISTED
Verona Pharma
VRNA
$958K 0.78%
47,723
-20,968
-31% -$453K
BMRN icon
38
BioMarin Pharmaceuticals
BMRN
$13.4B
$943K 0.77%
9,701
– –
XENE icon
39
Xenon Pharmaceuticals
XENE
$6.2B
$907K 0.74%
25,340
– –
PLRX icon
40
Pliant Therapeutics
PLRX
$65M
$905K 0.74%
34,035
-7,427
-18% -$211K
CLDX icon
41
Celldex Therapeutics
CLDX
$3.49B
$890K 0.73%
24,742
– –
KRYS icon
42
Krystal Biotech
KRYS
$9.78B
$885K 0.72%
11,058
– –
GOOG icon
43
Alphabet (Google) Class C
GOOG
$4.25T
$884K 0.72%
8,500
+2,530
+42% +$244K
ARGX icon
44
argenx
ARGX
$53.9B
$869K 0.71%
2,333
– –
FOLD
45
DELISTED
Amicus Therapeutics
FOLD
$857K 0.7%
77,314
– –
MRUS
46
DELISTED
Merus
MRUS
$846K 0.69%
+45,957
New +$801K
ALNY icon
47
Alnylam Pharmaceuticals
ALNY
$29.5B
$812K 0.66%
4,056
– –
PTCT icon
48
PTC Therapeutics
PTCT
$6.13B
$801K 0.65%
+16,535
New +$756K
VTYX
49
DELISTED
Ventyx Biosciences
VTYX
$790K 0.64%
23,583
-9,673
-29% -$376K
ASND icon
50
Ascendis Pharma A/S
ASND
$16.7B
$787K 0.64%
7,338
– –
1
2
3 4 5

Similar funds

SIAG
Safeguard Investment Advisory Group Corona, California $362M AUM 20.96% 1-Year Est. Return
WI
WBI Investments Red Bank, New Jersey $362M AUM 23.75% 1-Year Est. Return
MS
Millington Securities Red Bank, New Jersey $362M AUM
WTFG
Wood Tarver Financial Group Boise, Idaho $362M AUM 14.75% 1-Year Est. Return
A6
Anchor @ 65 Singapore $362M AUM 20.02% 1-Year Est. Return
PI
Pennant Investors Summit, New Jersey $361M AUM 134.26% 1-Year Est. Return
ACM
Anfield Capital Management Irvine, California $363M AUM 24.08% 1-Year Est. Return
BCC
Bridge City Capital Lake Oswego, Oregon $361M AUM 38.29% 1-Year Est. Return

HighVista Strategies's Q1 2023 Portfolio in Review

As of Q1 2023, HighVista Strategies held 142 positions worth $123M, down 27% from $168M the previous quarter. Its ten largest holdings account for 29% of the portfolio.

HighVista Strategies withdrew a net $44.3M in Q1 2023, closing 34 positions and reducing 19 holdings. Its most notable exit was Dell, an estimated $14.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 67% of assets, up from 47% a quarter earlier, followed by Technology and Consumer Discretionary.

Against the trend, HighVista Strategies opened a new position in Horizon Therapeutics Public Limited Company Ordinary Shares worth $3.17M.

  • HighVista Strategies's largest Q1 2023 buy was Horizon Therapeutics Public Limited Company Ordinary Shares: 29,000 shares worth $3.17M.
  • HighVista Strategies added most to Seagen Inc. Common Stock in Q1 2023, an estimated $2.49M increase.
  • HighVista Strategies's biggest Q1 2023 reduction was Mastercard, cutting an estimated $12.9M.
  • HighVista Strategies fully exited Dell in Q1 2023, selling an estimated $14.3M.
  • HighVista Strategies's ten largest holdings make up 29% of its $123M portfolio in Q1 2023.
  • HighVista Strategies opened 37 new positions and closed 34 in Q1 2023.
  • HighVista Strategies's portfolio value fell 27% quarter-over-quarter to $123M.

Based on HighVista Strategies's 13F filing for Q1 2023, filed 15 May 2023.